(MedPage Today) -- This article includes a first-person perspective from early breast cancer patient Lina. Lina was compensated for her time by Novartis. Some patients with hormone receptor (HR)-positive, human epidermal growth factor receptor...

Send this story to anyone — or drop the embed into a blog post, Substack, Notion page. Every play sends rev-share back to MedPage Today.

𝕏 Post on X in Share on LinkedIn ✉ Email a friend

Heard via Storyflo

Get audio versions of every article you read.

Pick what matters — your audio curator gets you into your daily flo.

Join the listener waitlist